Argyle Capital Management LLC Has $8.67 Million Position in Eli Lilly and Company $LLY

Key Points

• Argyle Capital Management LLC has reduced its holdings in Eli Lilly and Company by 3.4%, resulting in a position valued at approximately $8.67 million.
• Analyst sentiments are mixed, with Morgan Stanley lowering its price target while others upgraded or maintained hold ratings, reflecting a range of perspectives on stock performance.
• Eli Lilly reported strong financial performance with earnings per share at $6.31, outperforming estimates and indicating significant year-over-year revenue growth of 37.6%.

Argyle Capital Management LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,127 shares of the company's stock after selling 390 shares during the period. Eli Lilly and Company comprises about 3.1% of Argyle Capital Management LLC's investment portfolio, making the stock its 2nd biggest holding. Argyle Capital Management LLC's holdings in Eli Lilly and Company were worth $8,674,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. WestEnd Advisors LLC lifted its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter valued at $27,000. Citizens National Bank Trust Department lifted its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company during the first quarter valued at $40,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on LLY. Morgan Stanley lowered their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research report on Friday, October 3rd. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. JPMorgan Chase & Co. lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 16th. Finally, HSBC boosted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $948.56.

Eli Lilly and Company Stock Up 1.0%

Shares of NYSE LLY opened at $854.40 on Friday. The stock has a 50 day moving average price of $740.99 and a 200 day moving average price of $766.49. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market capitalization of $808.66 billion, a price-to-earnings ratio of 55.84, a PEG ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Jamere Jackson bought 200 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.